Chennai Meenakshi Multispeciality Hospital has announced significant board-level changes following its meeting on August 11, 2026. The company has appointed Dr. Thanigai Vendan Moorrthy as the new Chief Executive Officer for a five-year term. Additionally, the board approved the appointment of three new Independent Directors: Mr. A F Simeon Telfer, Mr. R V Ramanuja Bharathi, and Ms. Sindu Chawla, each for a five-year term, subject to shareholder approval. The reconstitution of the Audit Committee and Stakeholders Relationship Committee has also been approved.
Key Leadership Appointments
The Board of Directors of Chennai Meenakshi Multispeciality Hospital convened on August 11, 2026, to consider and approve several critical appointments and financial results. The meeting, which commenced at 11:30 AM and concluded at 3:15 PM, marked a significant step in the company’s strategic and governance evolution.
New Chief Executive Officer
A major decision was the appointment of Dr. Thanigai Vendan Moorrthy as the Chief Executive Officer (CEO) in a non-director capacity. Dr. Moorrthy’s appointment is effective from August 11, 2026, and he will serve for a term of five consecutive years. His extensive background as a Senior Anesthesiologist and Healthcare Executive with over 15 years of clinical and leadership experience is expected to drive operational excellence and strategic growth for the hospital.
Board Expansion with Independent Directors
Further strengthening the board’s oversight, three new Independent Directors have been appointed. These appointments are:
- Mr. A F Simeon Telfer (DIN: 11879121), appointed as an Additional Non-Executive Independent Director.
- Mr. R V Ramanuja Bharathi (DIN: 08553270), appointed as an Additional Non-Executive Independent Director.
- Ms. Sindu Chawla (DIN: 11879201), appointed as an Additional Non-Executive Independent Director.
Each of these appointments is effective from August 11, 2026, for a term of five consecutive years. Their tenure is subject to the approval of the shareholders at the ensuing Annual General Meeting and will not be liable to retire by rotation. These directors bring diverse expertise, including business development, strategic planning, legal strategy, and software engineering leadership.
Committee Reconstitution
Consequent to the appointment of new directors, the Board has also approved the reconstitution of its key committees, effective from August 11, 2026:
Audit Committee
The reconstituted Audit Committee will include Mr. M. Karunakaran (Chairman), Mr. A F Simeon Telfer (Member), and Mrs. Jayanthi Radhakrishnan (Member).
Stakeholders Relationship Committee
The Stakeholders Relationship Committee will now comprise Ms. Sindu Chawla (Chairman), Mr. R V Ramanuja Bharathi (Member), and Mr. Edward Prabhakar (Member).
Financial Results
The Board also considered and approved the unaudited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report submitted by the Statutory Auditors. These results, enclosed as Annexure A, indicate the company’s financial performance during the period.
Source: BSE
